View Item 
      •   UMY Repository
      • 03. DISSERTATIONS AND THESIS
      • Students
      • Undergraduate Thesis
      • Faculty of Medicine and Health Science
      • Department of Pharmacy
      • View Item
      •   UMY Repository
      • 03. DISSERTATIONS AND THESIS
      • Students
      • Undergraduate Thesis
      • Faculty of Medicine and Health Science
      • Department of Pharmacy
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      COST EFFECTIVENESS ANALYSIS PENGGUNAAN CAPTOPRIL DAN AMLODIPIN PADA PASIEN HIPERTENSI PRIMER DI PUSKESMAS BANTUL I

      Thumbnail
      View/Open
      COVER (220.2Kb)
      HALAMAN JUDUL (342.9Kb)
      LEMBAR PENGESAHAN (301.5Kb)
      ABSTRAK (201.2Kb)
      BAB I (333.8Kb)
      BAB II (681.9Kb)
      BAB III (477.0Kb)
      BAB IV (461.1Kb)
      BAB V (197.2Kb)
      DAFTAR PUSTAKA (423.8Kb)
      LAMPIRAN (900.3Kb)
      NASKAH PUBLIKASI (748.6Kb)
      Date
      2019-06-26
      Author
      PERMATASARI, INTAN
      Metadata
      Show full item record
      Abstract
      Hypertension is a disease called sillent killer, its mean this disease can kill without causing symptoms. Hipertension in the long term can cause complications to other organs. Treatment of primary hypertension is carried out with long-term therapy even for a lifetime to get a better quality of life besides hypertension has a fairly high prevalence rate so that the burden of costs incurred will also be even greater. This study aims to determine the results of the study of Cost Effectiveness Analysis of antihypertensive use of Captopril and Amlodipine according to the perspective of health care providers in primary hypertensive patients at the Bantul I Health Center. This study uses a retrospective cohort design with total sampling data collection techniques. Retrieval of data from medical records of primary hypertensive patients on outpatient care in Bantul I Health Center. Subjects were patients taking Captopril and Amlodipine single antihypertensive of 156 patients. Data analysis in this study using univariate analysis in the form of average costs and effectiveness and pharmacoeconomic analysis in the form of ACER and ICER values. The average cost used according to the perspective of health care providers is taken from the antihypertensive costs needed to achieve effectiveness while the average effectiveness is the percentage of patients who reach the normal target in the range of 2-4 weeks. The average cost of Amlodipine 5 mg is Rp. 29,520 and Captopril 25 mg is Rp. 11,133.33 and the average effectiveness of Amlodipine 5 mg is 59.06% and Captopril 25 mg is 50%, so the ACER value for Amlodipine 5 mg Rp.499.83 and Captopril 25 mg is Rp222.66. ACER results showed that Amlodipine 5 mg and Captopril 25 mg needed ICER calculation because Amlodipin 5 mg had high effectiveness at high cost and Captopril 25 mg had low effectiveness at low cost. The ICER results in Amlodipine 5 mg with the antihypertensive alternative Captopril 25 mg were Rp2,029.43. So it takes additional expenses Rp2.029,43 for each 1% increase in effectiveness of Captopril 25 mg.
      URI
      http://repository.umy.ac.id/handle/123456789/32092
      Collections
      • Department of Pharmacy

      DSpace software copyright © 2002-2015  DuraSpace
      Contact Us | Send Feedback
      Theme by 
      @mire NV
       

       

      Browse

      All of UMY RepositoryCollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

      My Account

      Login

      DSpace software copyright © 2002-2015  DuraSpace
      Contact Us | Send Feedback
      Theme by 
      @mire NV